Pα+ Psychedelic Patent Analysis: March 2024 – Psychedelic Alpha

General Overview
First Look at Nolan Williams et al.’s Ibogaine IP: Is Co-Administration of Magnesium and Ibogaine Common Practice?
Clexio Biosciences Protects CLE-100 Development Programs
Broad Strokes Attempt from Axsome Fails to Overcome Prior Art
NYU Abandons “Hot Psilocybin Patent Garbage”

***

Each month, we provide an interactive database of psychedelic patents that were granted, allowed, abandoned, rejected or that had responses filed.

We then provide detail and analysis on a handful of specific cases, or one deep dive.

Our monthly Psychedelic Patent Analysis is exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.

Companies, organisations and candidates mentioned in this analysis: DemeRx, Axsome Therapeutics, Empyrean Neuroscience, Tactogen, Clexio Biosciences, CLE-100, Gilgamesh Pharmaceuticals, MindMed, Awakn Life Sciences, and others.

First Oral JAK Inhibitor Approved for Severe Alopecia Areata in Teens

The FDA approved the Janus kinase (JAK) inhibitor ritlecitinib (Litfulo) for adults and adolescents with severe alopecia areata. Ritlecitinib is the second oral JAK inhibitor

June 27, 2023

What Did New Data Show About Drinking Wine?

The 24-hour news cycle is just as important to medicine as it is to politics, finance, or sports. At MedPage Today, new information is posted

December 22, 2024

How next-gen sequencing is changing antibody drug discovery

New study outlines how next-generation sequencing (NGS) and machine-learning methods can revolutionize antibody discovery, particularly against SARS-CoV-2. The research demonstrates that NGS provides greater epitopic

October 31, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.